X
Aug 23, 2021 01:32 PM (GMT+8) · EqualOcean
Sun piaoyang, chairman of Hengrui pharmaceutical, said at the investor exchange meeting that the problems encountered by Hengrui are the problems encountered by almost all Chinese generic drug transformation and innovative drug enterprises, that is, the steep decline of generic drugs and the gradual growth of innovative drugs“ The development of enterprises should develop orderly according to the rhythm of enterprises, not according to the rhythm of the secondary market, and it is impossible to operate according to the fluctuation of stocks every day. " Referring to Hengrui's recent performance in the secondary market, sun piaoyang said that Hengrui has two strategies that will never change: one is scientific and technological innovation, the other is internationalization, and constantly establish new technology platforms around this strategy.

This text is a result of machine translation.